These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 36431875)

  • 1. Dihydrotanshinone I Inhibits the Proliferation and Growth of Oxaliplatin-Resistant Human HCT116 Colorectal Cancer Cells.
    Wang M; Xiang Y; Wang R; Zhang L; Zhang H; Chen H; Luan X; Chen L
    Molecules; 2022 Nov; 27(22):. PubMed ID: 36431875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostaglandin F
    Wang YJ; Xie XL; Liu HQ; Tian H; Jiang XY; Zhang JN; Chen SX; Liu T; Wang SL; Zhou X; Jin XX; Liu SM; Jiang HQ
    World J Gastroenterol; 2023 Oct; 29(39):5452-5470. PubMed ID: 37900995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. β-hydroxybutyrate resensitizes colorectal cancer cells to oxaliplatin by suppressing H3K79 methylation in vitro and in vivo.
    Deng M; Yan P; Gong H; Li G; Wang J
    Mol Med; 2024 Jun; 30(1):95. PubMed ID: 38910244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LncRNA CACS15 contributes to oxaliplatin resistance in colorectal cancer by positively regulating ABCC1 through sponging miR-145.
    Gao R; Fang C; Xu J; Tan H; Li P; Ma L
    Arch Biochem Biophys; 2019 Mar; 663():183-191. PubMed ID: 30639170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IFI6 Downregulation Reverses Oxaliplatin Resistance of Colorectal Cancer Cells by Activating the ROS-Induced p38MAPK Signaling Pathway.
    Huang C; Zhou T; Ma L; Zhao S
    Biol Pharm Bull; 2023; 46(1):26-34. PubMed ID: 36596524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shikonin potentiates therapeutic efficacy of oxaliplatin through reactive oxygen species-mediated intrinsic apoptosis and endoplasmic reticulum stress in oxaliplatin-resistant colorectal cancer cells.
    Zhang Z; Shen C; Zhou F; Zhang Y
    Drug Dev Res; 2023 May; 84(3):542-555. PubMed ID: 36779379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression MGP inhibits tumor proliferation and reverses oxaliplatin resistance in colorectal cancer.
    Huang C; Wang M; Wang J; Wu D; Gao Y; Huang K; Yao X
    Biochem Pharmacol; 2021 Jul; 189():114390. PubMed ID: 33359068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR1/P-gp expression.
    Zhou H; Lin C; Zhang Y; Zhang X; Zhang C; Zhang P; Xie X; Ren Z
    Cell Prolif; 2017 Jun; 50(3):. PubMed ID: 28217977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Synergistic effect of polysaccharide from
    Li P; Yuan P; Que Y; Liu X; Wang G
    Nan Fang Yi Ke Da Xue Xue Bao; 2021 Apr; 41(4):504-513. PubMed ID: 33963708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis.
    Hsu HH; Chen MC; Baskaran R; Lin YM; Day CH; Lin YJ; Tu CC; Vijaya Padma V; Kuo WW; Huang CY
    J Cell Physiol; 2018 Jul; 233(7):5458-5467. PubMed ID: 29247488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of Notch and Wnt signaling for chemoresistance of colorectal cancer cells HCT116.
    Kukcinaviciute E; Jonusiene V; Sasnauskiene A; Dabkeviciene D; Eidenaite E; Laurinavicius A
    J Cell Biochem; 2018 Jul; 119(7):5913-5920. PubMed ID: 29637602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unraveling the immune landscape and therapeutic biomarker PMEPA1 for oxaliplatin resistance in colorectal cancer: A comprehensive approach.
    Zhang Z; Lu T; Zhang Z; Liu Z; Qian R; Qi R; Zhou F; Li M
    Biochem Pharmacol; 2024 Apr; 222():116117. PubMed ID: 38461903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P53‑microRNA interactions regulate the response of colorectal tumor cells to oxaliplatin under normoxic and hypoxic conditions.
    Zhang J; Li C; Sun L; Sun D; Zhao T
    Oncol Rep; 2023 Dec; 50(6):. PubMed ID: 37921068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dihydromyricetin reverses MRP2-induced multidrug resistance by preventing NF-κB-Nrf2 signaling in colorectal cancer cell.
    Wang Z; Sun X; Feng Y; Wang Y; Zhang L; Wang Y; Fang Z; Azami NLB; Sun M; Li Q
    Phytomedicine; 2021 Feb; 82():153414. PubMed ID: 33461143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kruppel-like factor 5 enhances proliferation, lipid droplet formation and oxaliplatin resistance in colorectal cancer by promoting fatty acid binding protein 6 transcription.
    Zuo Q; Xu Q; Li Z; Luo D; Peng H; Duan Z
    Anticancer Drugs; 2023 Nov; 34(10):1171-1182. PubMed ID: 37067981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of MEG3 sensitizes colorectal cancer cells to oxaliplatin through regulation of miR-141/PDCD4 axis.
    Wang H; Li H; Zhang L; Yang D
    Biomed Pharmacother; 2018 Oct; 106():1607-1615. PubMed ID: 30119236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-tumor potential of 15,16-dihydrotanshinone I against breast adenocarcinoma through inducing G1 arrest and apoptosis.
    Tsai SL; Suk FM; Wang CI; Liu DZ; Hou WC; Lin PJ; Hung LF; Liang YC
    Biochem Pharmacol; 2007 Dec; 74(11):1575-86. PubMed ID: 17869226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioactive Peptides Sensitize Cells to Anticancer Effects of Oxaliplatin in Human Colorectal Cancer Xenografts in Nude Mice.
    Li X; Xia L; Ouyang X; Suyila Q; Su L; Su X
    Protein Pept Lett; 2019; 26(7):512-522. PubMed ID: 30950338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose orlistat promotes the therapeutic effect of oxaliplatin in colorectal cancer.
    Zhang Q; Zhou Y; Feng X; Gao Y; Huang C; Yao X
    Biomed Pharmacother; 2022 Sep; 153():113426. PubMed ID: 36017794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The c-Myc/miR-27b-3p/ATG10 regulatory axis regulates chemoresistance in colorectal cancer.
    Sun W; Li J; Zhou L; Han J; Liu R; Zhang H; Ning T; Gao Z; Liu B; Chen X; Ba Y
    Theranostics; 2020; 10(5):1981-1996. PubMed ID: 32104496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.